Available online on 15.04.2025 at http://jddtonline.info
Journal of Drug Delivery and Therapeutics
Open Access to Pharmaceutical and Medical Research
Copyright © 2025 The Author(s): This is an open-access article distributed under the terms of the CC BY-NC 4.0 which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited
Open Access Full Text Article Review Article
Novel Nanocarriers Microencapsulation: Current, Patents and Clinical Trials Comprehensive Review
Aileen Tressa 1, Anshika Singh *1, Rahul Pal 2, Nandlal Kumar 3
1 UG Scholar, ISF College of Pharmacy (ISFCP), Moga, GT Road, 142001, Punjab, India.
2 Assistant Professor, Department of Pharmaceutics, ISF College of Pharmacy (ISFCP), Moga, GT Road, 142001, Punjab, India.
3 UG Scholar, Department of Paramedical, Nims College of Paramedical Technology, NIMS University, Jaipur, Rajasthan, 303121, India.
|
Article Info: _______________________________________________ Article History: Received 14 Jan 2025 Reviewed 05 March 2025 Accepted 22 March 2025 Published 15 April 2025 _______________________________________________ Cite this article as: Tressa A, Singh A, Pal R, Kumar N, Novel Nanocarriers Microencapsulation: Current, Patents and Clinical Trials Comprehensive Review, Journal of Drug Delivery and Therapeutics. 2025; 15(4):188-208 DOI: http://dx.doi.org/10.22270/jddt.v15i4.7103 _______________________________________________ *Address for Correspondence: Ms. Anshika Singh, UG Scholar, ISF College of Pharmacy (ISFCP), Moga, GT Road, 142001, Punjab, India |
Abstract _______________________________________________________________________________________________________________ The field of nanocarriers and microencapsulation has witnessed substantial growth, offering innovative solutions for drug delivery challenges. This comprehensive review explores the latest advancements in nanocarriers and microencapsulation technologies, focusing on their applications in enhancing drug stability, controlled release, and targeted delivery. The article highlights key breakthroughs, emphasizing their significance in addressing therapeutic inefficacies. A detailed analysis of current patents underscores the innovative strides in this domain, while insights into clinical trials provide a perspective on the translational potential of these technologies. This review article begins with a fundamental overview of microencapsulation, including its various types and characteristics. It intermediately delves into several formulation techniques associated with microencapsulation, examining the latest developments in prepared formulations, granted patents, and a selection of marketed products. Finally, the article addresses future prospects and the challenges that lie ahead in this field. Keywords: microencapsulation; entrapment; microcapsules; nanocarriers; advancements. |
Controlled drug delivery technology is one of the most rapidly advancing fields, addressing the limitations of conventional dosage forms while enhancing crucial aspects such as targeted drug delivery to specific organs or tissues and regulating the rate of drug release at the target site1-2. Developing an oral controlled-release system poses significant formulation challenges due to its difficulty in maintaining localization within specific areas of the gastrointestinal tract. However, with appropriate modifications, such systems can sustain the desired drug concentration at the site of interest without requiring external intervention3.
Nanocarriers and microencapsulation techniques have emerged as groundbreaking strategies in drug delivery, offering precise control over drug release, enhanced stability, and targeted delivery to specific sites. These advanced systems address critical challenges associated with conventional formulations, such as poor bioavailability (BA) and rapid degradation. Exploring their potential in improving therapeutic outcomes and addressing unmet clinical needs, the review provides a holistic perspective on the innovations shaping the future of drug delivery systems (DDs) 4-5. In microencapsulation, microcarriers such as microspheres and microcapsules form a multiparticulate DDs designed to target specific organs and tissues through a controlled drug release mechanism. This mechanism ensures that the outer layer safeguards the inner core, which contains the active pharmaceutical ingredients, from external conditions until the drug is needed for release6. The major factors that influence the drug delivery for microencapsulation carriers are as Table 1 follows:
Table 1: List of the major factors that influence drug delivery in terms of microcapsules/microencapsulation5-8
|
Factor |
Description |
Impact on Drug Delivery |
|
Core Material |
The drug or active ingredient encapsulated within the microcapsule. |
Determines the drug stability, solubility, and release profile. |
|
Wall Material |
The polymer or material used to form the outer shell of the microcapsule. |
Affects the encapsulation efficiency, release rate, and protection of the drug. |
|
Size and Shape |
Physical dimensions and morphology of the microcapsule. |
Influences drug release kinetics and biodistribution. |
|
Encapsulation Method |
Techniques like coacervation, spray drying, or solvent evaporation used to create microcapsules. |
Impacts the uniformity, size, and stability of the microcapsules. |
|
Drug Loading Capacity |
The amount of drug incorporated into the microcapsule relative to its total weight. |
Determines the dosage and efficacy of the formulation. |
|
Release Mechanism |
Methods like diffusion, erosion, or degradation by which the drug is released. |
Controls the timing and duration of drug release. |
|
Degradation Rate |
The rate at which the wall material breaks down in the body. |
Influences the release rate and biodegradability of the microcapsules. |
|
pH Sensitivity |
The microcapsule stability and release behavior under varying pH conditions. |
Allows targeted delivery in specific regions of the gastrointestinal tract (GIT). |
|
Stability |
Physical and chemical stability of the microcapsule during storage and use. |
Affects shelf life and therapeutic performance. |
|
Surface Properties |
Characteristics like hydrophobicity, charge, or roughness of the microcapsule surface. |
Impacts interaction with biological environments and drug uptake. |
|
Environmental Factors |
External conditions such as temperature, humidity, and light during storage or application. |
Influence the integrity and release profile of the microcapsules. |
Advantages and Disadvantages of Microencapsulation: The various merits and demerits for the selection of microencapsulation discussed as below Table 2.
Table 2: List of advantages and disadvantages of microencapsulation 8-10
|
Advantages |
Disadvantages |
|
Protects encapsulated ingredients from degradation by moisture, light, oxygen, etc. |
High cost due to materials and sophisticated equipment. |
|
Masks the bitter taste of the drug, improving palatability and patient compliance. |
Core particle stability is affected by changes in process conditions like temperature, pH, or solvent evaporation. |
|
Avoids incompatibilities in drug combinations. |
Stricter quality control requirements. |
|
Provides controlled release of active ingredients. |
Polymer matrix degradation due to heat, hydrolysis, or biological agents. |
|
Reduces major side effects like toxicity and gastrointestinal irritation. |
Complex manufacturing process and limited drug-loading capacity. |
|
Converts free-flowing liquids into solids or pseudo-solids, improving handling and storage. |
Reduces the shelf life of hygroscopic drugs. |
|
Preserves the volatility of compounds in the inner core. |
Technique is not adaptable to all types of drugs. |
|
Improves the flow property of the core drug. |
Probability of discontinuous coating. |
|
Masks unpleasant odors of certain drugs. |
Single methods cannot be applied to all core materials. Difficulties in scaling up production processes (small-scale and large-scale). May not be suitable for parenteral routes due to size restrictions. |
Need for Microencapsulation: The primary characteristic of microcapsules is their tiny particle size, which results in an extensive surface area. This increased surface area offers notable benefits, including enhanced absorption and desorption sites, facilitation of chemical reactions, and improved light scattering 11. Microencapsulation techniques play a crucial role, enabling the development of various dosage forms, such as transforming liquids into solids. This transformation addresses a significant challenge in microencapsulation: safeguarding against environmental factors. Additionally, it aids in the separation of reactive pharmaceutical components and enhances the handling properties of materials 11-12. In a variety, of cases there is a need for separation of the core from its surroundings because of the following reasons:
Microencapsulation, involving microspheres or microcapsules, is a critical advancement in DDs designed to address several challenges associated with conventional formulations. This technique enables controlled and sustained drug release, ensuring consistent therapeutic levels and reducing dosing frequency 13-14. It enhances the stability of sensitive drugs, protecting them from environmental factors such as light, moisture, and pH variations. Microencapsulation also facilitates targeted delivery to specific sites, minimizing systemic side effects and improving patient compliance. To optimizing drug solubility, BA, and release kinetics, microencapsulation has become an essential tool in modern pharmaceutical development 15.
In some cases, the main objective is not to separate the core from the outer surroundings but to control the release of drugs in its surrounding environment which can be achieved by microencapsulation 16. Overall microencapsulation enhances product functionality in various industries (Fig. 1) which are as follows: -
Figure 1: Application of microencapsulation
This comprehensive review article discuss the basics of microencapsulation with their structure, compositions and classifications on the types of carriers such as microcapsules and microsphere. The different methods of preparation involved in the formulation steps. The recent and current status in the preparation of nanocarriers with patent status and few marketed formulations. Lastly, the clinical trials on microencapsulation nanocarriers conducted in the targeting actions.
Microencapsulation nanocarriers are advanced drug delivery systems designed to encapsulate active ingredients within nanoscale carriers for targeted delivery and controlled release. Their structure typically comprises a core containing the active substance, surrounded by a protective shell or matrix material 17-18. The composition varies based on the application and may include biodegradable polymers (PLGA, chitosan), lipids (Phospholipids), or proteins. These nanocarriers are classified into different types, especially nanospheres (solid matrix systems) and nanocapsules (distinct core-shell structures) offering unique properties for specific therapeutic or industrial purposes 19. The brief description about this as below following:
Microspheres are solid spherical particles with a uniform distribution of the active ingredient throughout the matrix. They do not have a distinct core-shell structure but provide controlled drug delivery and improved BA 21.
Microspheres are spherical particles, typically ranging in size from 1-1000 µm, composed of natural or synthetic materials. Apart from microcapsules, microspheres have a uniform matrix structure without a distinct core-shell design. They are commonly used in DDs due to their ability to encapsulate active ingredients and provide controlled, sustained, or targeted release. Microspheres can be biodegradable (Made of PLA, PGA, or PLGA) or non-biodegradable (PMMA) 21-22. Their applications extend to pharmaceuticals, diagnostics, and imaging, offering enhanced BA, reduced dosing frequency, and improved therapeutic outcomes.
Microcapsules are spherical structures composed of a core material (API) surrounded by a distinct coating layer. The coating provides controlled release, protection from environmental factors, or taste masking 23.
Microcapsules are tiny spherical particles with a distinct core-shell structure, where the core contains the active ingredient, and the shell provides a protective coating. Their sizes range from 1 µm to several millimeters. The shell material, often made of polymers, lipids, or proteins, helps protect the core from environmental factors and allows controlled or sustained release of the encapsulated substance 22-24. Microcapsules are widely used in pharmaceuticals, food, agriculture, and cosmetics for applications like drug delivery, flavor masking, and enhanced stability of volatile or sensitive compounds.
Microcapsules are categorized into controlled release types, designed for gradual drug or nutrient release, and burst release types, which rapidly deliver the core material. The manufacturing methods further classify them into chemical microcapsules (produced via coacervation or polymerization) and physical microcapsules (formed through spray drying or extrusion) 25. These diverse types make microcapsules adaptable for pharmaceuticals, food, and industrial applications. Microcapsules classified in the various parts (Fig. 2) as below following
:
Figure 2: Representation of types of microcapsules nanocarrier
The description of the types of microcapsules mentioned in the given Table 3 as below following:
Table 3: List of description about the types and description of types of microcapsules 25-27
|
Type of Microcapsule |
Description |
Structure |
|
Mononuclear/Single Core |
A single core containing the active ingredient is enclosed within a single shell. Made of organic compounds, artificial materials, or polymers. |
|
|
Poly-nuclear/Multiple-Core |
Multiple core particles containing active ingredients are enclosed within a single shell. Provides consistent release due to the presence of multiple cores. |
|
|
Matrix Type |
Core material is uniformly distributed throughout a solid matrix. Provides controlled release based on matrix composition. |
|
|
Multi-Wall Type |
Core material is enclosed within multiple shell layers, offering enhanced protection and gradual release. |
|
|
Irregular Microcapsules |
Core and shell are non-uniform or asymmetric in shape. Often used for burst release patterns. |
|
This classification highlights the diversity in microcapsule design, catering to various applications requiring controlled, sustained, or burst release. Microcapsules have a core-shell structure, where the API is enclosed within a protective shell, enabling controlled release or protection. Microspheres are solid matrix systems where the API is uniformly distributed throughout, allowing sustained or targeted release 28. While microcapsules are ideal for applications requiring a distinct core-shell design, microspheres are better suited for uniform release profiles and enhanced BA 29. Both systems serve diverse purposes in pharmaceuticals, diagnostics, and industrial applications. The comparison of microencapsulation brief discussed as below Table 4.
Table 4: The comparison Between Microcapsules and Microspheres 29-30
|
Characteristic |
Microcapsules |
Microspheres |
|
Structure |
Core-shell |
Matrix-like |
|
Encapsulation Type |
Single core surrounded by coating |
Uniform distribution of core material |
|
Release Profile |
Controlled, burst, or delayed |
Controlled, sustained release |
|
Applications |
Food, pharmaceuticals, cosmetics |
Drug delivery, diagnostics, imaging |
This classification highlights the diversity and adaptability of microencapsulation techniques in drug delivery and other industrial applications 31. The both nanocarriers for microencapsulation have their several offering advantages and benefits in the loading and encapsulation of medicament and targeting treatment.
Figure 3: Representation of structure of microsphere/microcapsules with their parts 34
The both structures are tailored for specific applications, such as drug delivery, diagnostics, or industrial use, by selecting appropriate materials and methods.
The structure, composition, and types of microencapsulation nanocarriers play a crucial role in optimizing DDs. Their versatile designs, including core-shell and matrix structures, enable precise control over release profiles, enhanced stability, and targeted delivery 34-35. Tailoring the composition and type such as nanospheres, nanocapsules, these carriers provide innovative solutions for therapeutic and industrial applications, ensuring efficiency and improved outcomes.
Microencapsulation techniques encompass a range of methodologies designed to enclose active substances within a protective coating or matrix, ensuring controlled release and stability. The common techniques include spray drying, coacervation (phase separation for capsule formation), emulsion-based methods (oil-in-water or water-in-oil emulsions for polymer encapsulation), and solvent evaporation/extraction (removal of solvents to solidify the capsule). Other advanced methods like fluidized bed coating, interfacial polymerization, and freeze-drying are also employed to tailor capsule size, release kinetics, and stability for specific applications 36. The brief discussion about the techniques involved in the preparation of microencapsulation discussed as below following:
In spray drying, the process begins with preparing a feed solution or dispersion by dissolving or dispersing the core material (API) in a suitable polymer solution or solvent system, ensuring uniform mixing. This solution is then fed into a spray dryer using a peristaltic pump, where it is atomized into fine droplets using a spray nozzle. The droplets are introduced into a hot air stream within the drying chamber, leading to rapid solvent evaporation and solid microsphere formation 37. The dried particles are collected at the bottom of the cyclone separator, and, sieved or characterized for size and encapsulation efficiency %EE (Fig. 4) as below.
Figure 4: Representation of preparation of microencapsulation carrier by spray drying/cooling 38
In spray cooling (congealing), the core material is dispersed or dissolved in a molten polymer matrix, which is maintained at an appropriate temperature to ensure liquidity. This molten mixture is atomized into fine droplets and introduced into a cooling chamber containing chilled air or another cooling medium. The droplets solidify upon cooling, forming microspheres or microcapsules. The solidified particles are then collected 39.
The IGM is a widely employed technique for the preparation of microspheres and microcapsules, particularly for hydrophilic polymers such as alginate, chitosan, or their derivatives. This method involves the crosslinking of polymer solutions with multivalent cations (Calcium ions for alginate) to form a gel matrix under mild conditions 39-40. Typically, the polymer solution containing the drug or active ingredient is dropped into an ion-rich solution using a syringe or nozzle, forming spherical microspheres or microcapsules upon contact (Fig. 5) as below.
Figure 5: Representation of preparation of microencapsulation via IGM 40
Additionally, ionic gelation enables controlled release properties by adjusting factors such as polymer concentration, crosslinking agent type, and gelation time 40. The applications of this method span diverse fields, including drug delivery, nutraceuticals, and tissue engineering.
The preparation of microspheres or microcapsules via centrifugal extrusion begins by preparing two immiscible liquids: the core material and the encapsulating polymer solution. These liquids are fed into concentric nozzles of a rotating extrusion head, with the core material in the inner nozzle and the polymer solution in the outer nozzle. As the head rotates, the liquids are extruded simultaneously, forming a liquid jet. The centrifugal force generated by the rotation causes the jet to break into uniform droplets 41-42. These droplets are directed into a hardening or solidifying medium, typically a cooling bath or a crosslinking solution, where the encapsulating polymer solidifies to form stable microspheres or microcapsules. The formed particles are then collected, washed to remove residual materials, and dried (Fig. 6).
Figure 6: Representation of preparation of microencapsulation via CEM 40
The parameters such as nozzle size, rotation speed, and the viscosity of the liquids are carefully controlled to achieve uniform particle size and %EE 42.
The emulsification method is a versatile and widely used technique for preparing microspheres or microcapsules, particularly for hydrophobic polymers and drugs. This process involves creating a stable emulsion by dispersing a polymer solution containing the active ingredient into an immiscible continuous phase, typically oil or water, under constant stirring. The emulsion droplets act as microreactors where the polymer solidifies, trapping the drug within. Polymer solidification can occur through solvent evaporation, solvent diffusion, or thermal gelation, depending on the system (Fig. 7) 43.
Figure 7: Representation preparation of emulsification for microemulsification 40
The microspheres or microcapsules are then separated, washed, and dried.
The preparation of microspheres or microcapsules via FBC involves suspending solid particles, which serve as the core material, in an upward stream of heated air within a fluidized bed chamber. A polymer solution or dispersion, serving as the coating material, is sprayed onto the fluidized particles using a nozzle. As the droplets of coating material come into contact with the particles, the solvent evaporates due to the heated air, leaving behind a uniform coating layer on the surface of the cores. The process is repeated in cycles to achieve the desired coating thickness (Fig. 8). Once coated, the microspheres or microcapsules are collected 44.
Figure 8: Preparation steps for microencapsulation carriers via FBC method 40
Freeze-drying, or lyophilization, is a specialized technique used to prepare microspheres or microcapsules, particularly when preserving the structural integrity of sensitive bioactive compounds is crucial. The process begins with the preparation of a polymer solution containing the drug or active ingredient, followed by its dispersion or emulsification into droplets. These droplets are rapidly frozen, typically using liquid nitrogen or a cryogenic freezer, to form solid particles. The frozen particles are then subjected to sublimation under reduced pressure in a freeze-dryer. This step removes water or other solvents by converting ice directly into vapour without passing through the liquid phase 45. The result is dry, porous microspheres or microcapsules with improved stability and extended shelf life. Freeze-drying is ideal for heat-sensitive drugs or biologics, as it operates at low temperatures 45-46.
The hot-melt microencapsulation method is a thermal-based technique for preparing microspheres or microcapsules, particularly for hydrophobic drugs and polymers with low melting points. The process begins by heating the polymer above its melting point to form a uniform molten phase. The drug or active ingredient is then dispersed or dissolved within this molten polymer. The polymer-drug mixture is subsequently emulsified into a continuous phase, typically an aqueous solution containing a stabilizer or surfactant, under vigorous stirring. Upon cooling, the molten polymer solidifies into discrete microspheres or microcapsules, encapsulating the drug within 47. The solidified particles are collected by filtration or centrifugation, washed, and dried. This method avoids the use of organic solvents, making it suitable for environmentally sensitive applications. It offers the advantage of producing microspheres with high drug loading efficiency and controlled-release properties by varying polymer types, drug concentrations, and process parameters 46-47.
The extrusion/emulsion-solvent evaporation/solvent evaporation method is a versatile and widely used technique for preparing microspheres or microcapsules, particularly for encapsulating both hydrophilic and hydrophobic drugs. The process typically involves several steps, starting with the preparation of a polymer solution containing the drug in a suitable solvent. In the extrusion step, the polymer-drug solution is extruded through a needle or nozzle to form droplets, which are then dispersed into an immiscible continuous phase, such as oil or an aqueous phase containing surfactants. This forms an emulsion where the droplets act as the microreactors for the formation of microspheres 48-49. The emulsion is then subjected to solvent evaporation, where the solvent is gradually removed under reduced pressure or by stirring. As the solvent evaporates, the polymer solidifies, encapsulating the drug within solid microspheres or microcapsules (Fig. 9) as below.
Figure 9: Representation of holt-melt Extrusion/Emulsion-Solvent Evaporation/Solvent evaporation 50
After evaporation, the microspheres or microcapsules are collected, washed, and dried.
In this method initially dissolving or dispersing the core material (API) in a suitable polymer solution. A non-solvent or a second polymer is gradually added under continuous stirring, inducing phase separation and leading to the formation of a coacervate (polymer-rich phase). The coacervate droplets deposit around the core material, encapsulating it to form a coating. The system is stabilized by adjusting parameters such as temperature, pH, or ionic strength to solidify the coacervate layer 51. The encapsulated particles are then separated by filtration or centrifugation, washed to remove impurities, and dried to obtain the final microspheres or microcapsules (Fig. 10).
Figure 10: Preparation of microencapsulation via Coacervation Phase Separation 40
The method begins with dissolving the core material in a suitable solvent and mixing it with a polymer solution. The mixture is emulsified in an immiscible continuous phase, such as water or oil, under vigorous stirring to form droplets containing the core material and polymer. Encapsulation is achieved through methods like solvent evaporation, solvent extraction, or crosslinking. In solvent evaporation, the organic solvent is removed by heating or applying a vacuum, causing the polymer to precipitate around the core material. In solvent extraction, the solvent diffuses into the aqueous phase, leading to polymer deposition, while in crosslinking, chemical agents or physical methods like UV light or heat solidify the polymer shell around the core 52-53. The resulting microspheres or microcapsules are then collected and dried.
The preparation of hydrogel microspheres involves dissolving or dispersing the core material in a hydrogel-forming polymer solution, such as alginate or chitosan. This solution is then extruded dropwise into a crosslinking or gelation medium, such as calcium chloride for alginate, where the polymer undergoes ionic or covalent crosslinking to form hydrogel beads encapsulating the core material 54-55. The formed microspheres are collected, washed to remove residual reagents, and dried or stored in hydrated form, depending on the application.
The preparation of microspheres or microcapsules via polymer-polymer incompatibility involves dissolving two incompatible polymers in a common solvent, along with the core material. Under controlled conditions, one polymer precipitates due to phase separation, forming a polymer-rich coacervate that encapsulates the core material. The second polymer remains in solution, stabilizing the dispersion. The system is further treated by solvent removal (evaporation or extraction) to solidify the encapsulating polymer layer. The resulting microspheres or microcapsules are collected by filtration or centrifugation, washed to remove residual materials, and dried 56.
These all above methods widely utilized in the formulation of microencapsulation such as microspheres and microcapsules of various drugs for the treatment of targeting. These techniques collectively enable innovative applications across pharmaceuticals, food, and cosmetic industries.
Microencapsulated nanocarriers are at the forefront of modern DDs, offering enhanced therapeutic efficacy through controlled and targeted release. Recent advancements focus on developing biocompatible and biodegradable materials such as polymers and lipids for encapsulation, improving drug stability and minimizing side effects 61. Innovations include stimuli-responsive nanocarriers that release drugs in response to pH, temperature, or enzymatic activity, and dual-functional carriers for combined therapy and imaging. Currently, their application spans pharmaceuticals, nutraceuticals, and cosmetics, with significant progress in cancer therapy, vaccines, and chronic disease management, demonstrating their transformative potential in personalized medicine 61-62. The recent status in term of prepared microsphere/microcapsules with their details, granted patent status and few marketed formulations mentioned in the Table 5, Table 6 and Table 7 respectively as below description.
Table 5: List of prepared microencapsulated nanocarriers with their details
|
Microencapsulated nanocarriers |
API /Drug |
Methods of preparations |
Compositions |
Research Outcomes |
Ref. |
|
Microcapsules |
Albendazole |
--- |
Albendazole + sodium alginate + Chitosan + HPMC + Cacl2 |
Albendazole-loaded chitosan alginate based microspheres can be effectively used for colon targeting |
[65] |
|
Aceclofenac |
Emulsion solvent evaporation method |
Aceclofenac + Ethyl cellulose (EC) |
They followed the Higuchi model and a released pattern of over 12 hr. was observed. |
[66] |
|
|
Trihexyphenidyle HCl |
Solvent evaporation method
|
Trihexyphenidyle + Methacrylic acid + Paraffin + Petroleum ether + Span80 + Acetone |
Trihexyphenidyle microcapsules can be successfully designed to develop sustained drug-delivery capsules |
[67] |
|
|
Cefotaxime sodium (CFs) |
CFs + Eudragit + Span80 |
In-vitro studies show that the release ratio kept ß as the polymer ratio kept increasing, the drug was sustained release. |
[68] |
||
|
Carvedilol |
Orifice gelation and co-grinding technique |
Carvedilol + Hydroxypropyl beta cyclodextrin + Sodium alginate + Eudragit NE30D(30) |
In-vivo studies show that optimized formulation was effective in controlling hypertension for a period of 24 Hr. |
[69] |
|
|
Diclofenac sodium (DS) |
Emulsion solvent evaporation technique |
DS + EC + Sodium carboxy methyl cellulose (CMC) + Chloroform + HCl + Methanol |
In in-vitro studies, the drug release profile decreased on increasing polymer concentration, and in in-vivo studies still to be carried out on the animal model. |
[70] |
|
|
Verapamil HCl |
Hot melt technique |
Verapamil HCl + EC acetate + Cyclohexane + n-hexane + Acetone |
In-vitro sustained release of verapamil have been established and in-vivo release are still to be confirmed in trials. |
[71] |
|
|
Valacyclovir HCl |
Solvent evaporation |
Valacyclovir HCl + Acetone + Liquid paraffin + Span 80 |
Good %EE and sustained released behavior were noticed in EC shell encapsulation. |
[72] |
|
|
Microspheres |
Pantoprazole Sodium (PPs) |
Nonaqueous solvent evaporation method |
PPs + HPMC K100M + Eudragit S100 + Ethanol + Dichloromethane (DCM) |
Micro particulate floating dose type of PPs can be effectively intended to give delayed arrival of medication and thus enhanced BA. |
[73] |
|
5-Fluorouracil (5-FC) |
Emulsion dehydration method and solvent evaporation method |
5-FC + Chitosan + Distilled water/Isooctane/Acetone + Span80 + Eudragit S100 + Liquid paraffin + n-hexane |
The prepared microspheres of 5-FC for colon targeting may reduce the side effects of the drug caused by its absorption from the upper part of GIT when given in conventional dosage forms. |
[74] |
|
|
Telmisartan |
Emulsion solvent evaporation method |
Eudragit 100 + Sodium lauryl sulfate (SLS) + Disodium hydrogen phosphate + Potassium dihydrogen phosphate + Polyvinyl alcohol (PVA) + Chloroform/sodium hydroxide/Chloride/methanol/HCl |
The formulations have shown good drug release in simulated intestinal medium, which is the desired medium for drug absorption. |
[75] |
|
|
Famotidine |
Ionotropic gelation technique |
Crude A + nilotica gum + Sodium alginate + Acacia nilotica + AlCl3/BaCl2/CaCl2 + distilled water |
Formulation with A. nilotica gum may be utilized during pharmaceutical dose frames by giving support to drug delivery system and avoiding side effects for the patients. |
[1] |
|
|
Ciprofloxacin |
Emulsion solvent diffusion evaporation method |
Ciprofloxacin + EC HPMC (100M) + Carbomer (934P) |
EC microspheres showed reproducible results, with good Mucoadhesive properties and good surface morphology. |
[77] |
|
|
Diacerein |
Ionotropic gelation method |
Diacerein + CaCl2 + sodium alginate + Chitosan |
The B3 formulation was the optimized formulation that gave the best results. |
[78] |
|
|
Glipizide |
Emulsification phase separation technique |
Glipizide + Chitosan + acetic acid + sodium acetate + dioctyl Sodium sulfosuccinate + Petroleum ether |
Mucoadhesive microspheres of glipizide could sustain the release of the drug for more than 12 hours. |
[79] |
|
|
Metformin HCl |
Ionic gelation technique |
Metformin HCl + xanthan gum + aluminium trichloride + NaCl + HCl |
The microparticles formulated with xanthan gum could be successfully used for the controlled release of drugs but also for the protection of pH-sensitive active ingredients, which could be degraded under the acidic conditions of the stomach. |
[80] |
|
|
Floating microspheres |
Metformin HCl + Eudragit + HPMC |
Showed excellent floatability, good buoyancy and prolonged drug release. |
[81] |
||
|
Efavirenz |
Solvent evaporation method |
Efavirenz + EC N-22 + EC 100 CPS + Eudragit RS PO + Acetone |
F14 contains Drug & Eudragit in the ratio of 1:1, which has a % yield of 94.12%,% %EE of 98.78% & the drug release of 96.82% at the end of 12 hrs when compared to other formulations. |
[82] |
|
|
Sulforaphane |
Spray drying Technique |
Iron (II) chloride tetrahydrate/hexahydrate + Ammonium hydroxide + Bovine Serum albumin + Deionized water + Glutaraldehyde + R/S sulforaphane |
Sulforaphane exerts anticancer activity in melanoma cells in vitro. Inhibition of HDAC was also observed when the cells were treated with sulforaphane, suggesting that this is a potential MOA, along with induction of apoptosis. |
[83] |
|
|
Human insulin |
Emulsion solvent evaporation technique |
Human insulin + Glycerol + Zinc oxide + Aprotinin + HCl + Methacrylic acid (EudragitS-100) + DCM/ethanol/IPA/PVA + Purified water |
Satisfactory performance of PVA-stabilized microspheres (F6) with respect to better %EE and delayed in vitro release at neutral pH for recombinant human insulin from Eudragit S100 microspheres. |
[84] |
|
|
Stavudine |
Emulsion solvent diffusion technique |
Stavudine + Acetone + Light liquid paraffin + n-Hexane |
The drug-to-polymer ratio and stirring speed are imperative to acquire sustained release and %EE. |
[85] |
|
|
5- Fluorouracil |
O/W emulsification solvent evaporation |
5-FU + Eudragit S100 + Eudragit L 100 + PVA + Methylene chloride |
At pH 7.4, nearly immediate release (within 30 min) was observed for pure S100, while mixtures enabled to prolong the release slightly. |
[86] |
|
|
Flurbiprofen |
Ionotropic gelation method |
Flurbiprofen + HPMC + Sodium Alginate + CaCl2 + Chitosan |
Flurbiprofen shows maximum absorption in the lower GIT regions, and shows half-life 4-5 h, it shows low BA orally. |
[87] |
|
|
Tinidazole |
Emulsion cross linking method |
Tinidazole + Bovine serum albumin + Span 80 + Glutaraldehyde + Toluene |
When the polymer concentration increases, drug %EE also increases. |
[88] |
|
|
Ketoprofen |
Solvent evaporation technique |
Ketoprofen + Acrycoat S 100 + PVA + Ethanol + DCM |
Ketoprofen loaded Acrycoat S 100 microsphere may be useful to achieve sustained drug. |
[89] |
|
|
Pantoprazole |
Solvent evaporation and solvent extraction |
Pantoprazole sodium + HPMC + Sod. Alginate + Liquid paraffin + IPA + NaOH + Acetone + DCM |
The formulation B1 was considered as the best formulation as the percentage drug release was found to be 91.352% in the presence of PBS of pH 7.4 after 14hrs which is the greatest among all. |
[90] |
|
|
Diltiazem HCl |
Solvent evaporation method |
Diltiazem HCl + Eudragit RS 100 + PEG 6000 + Liquid paraffin + Petroleum ether |
Diltiazem HCl can be formulated as prolonged/sustained release drug delivery system with Eudragit RS 100. |
[91] |
|
|
Metformin |
Emulsion solvent evaporation method |
Metformin + EC + DCM + Tween-80 + Span 80 + Guar gum |
Microcapsules prepared with guar gum as matrix material could be a suitable CR dosage form of metformin having high DEE that may release less amount of drug in stomach minimizing the emergence of gastric adverse effects. |
[92] |
This Table 5 mentioned all details of prepared microencapsulation nanocarriers with their several details and enhanced the treatment of different disease and targeting.
Table 6: List of granted/published patent on microencapsulated nanocarriers with their targeting details
|
Types of Patent Category |
Entitle |
Application No./CBR/Grant No. |
Patent No. |
Applicants/Inventor |
Filling Date |
Published/Grant/Date of Patent |
|
US
|
Microsphere Formulations Comprising Lurasidone and Methods for Making and Using the Same |
17 / 679,385 |
US 2022/ 0265562 A1 |
Spencer et al. |
Feb. 24, 2022 |
Aug. 25, 2022 |
|
Method and apparatus for formulating microspheres and microcapsules |
09/687,706 |
US 6,361,798 B1 |
Thanoo et al. |
Oct. 13, 2000 |
Mar. 26, 2002 |
|
|
Process for preparation of microspheres
|
193977 |
US4933105A |
Jones W. Fong |
May 13, 1988 |
Jun. 12, 1990 |
|
|
Intravitreal microsphere drug delivery and method of preparation |
455,091 |
US5718922A |
Herrero-Vanrell et al. |
May 31, 1995 |
Feb. 17, 1998 |
|
|
Synthesis of functionalized carbon microspheres and their catalyst activity in C-O and C-N bond formation reactions |
15/911018 |
US10195599 |
Ankush Venkatrao Biradar et al. |
02-03-2018 |
05-02-2019 |
|
|
Continuous process for preparing microspheres and microspheres prepared thereby |
14 / 278, 035 |
US10195149B2 |
Kim et al. |
May 15 , 2014 |
Feb. 5 , 2019 |
|
|
EP |
Gastroretentive controlled release microspheres for improved drug delivery |
98924438.9 |
EP0984774B1 |
ILLUM, Lisbeth et al. |
22.05.1998 |
14.07.2004 |
|
Method For Producing Microspheres Loaded With DruSgs And Microspheres Loaded With Drugs Produced Thereby |
07808011.6 |
EP2063874B1 |
Hong Kee Sah |
31.08.2007 |
03.04.2013 |
|
|
CA |
Controlled release biodegradable micro- and nanospheres containing cyclosporine |
1996/000017 |
CA2217462C |
Zebunnissa Ramtoola |
1996-04-02 |
2010-08-03 |
|
CN |
Preparation method of drug-carrying microspheres |
201110142359 |
CN 201110142359 |
朱利民聂伟申夏夏 |
2011-05-30 |
2013-01-02 |
|
WIPO (PCT) |
Method of preparing microcapsules |
2004/000803 |
WO2004105734A1 |
Patrice Hildgen et al. |
2004-12-09 |
2004-12-09 |
This Table 6 above mentioned the several patent on the microencapsulation, with their all required details briefly. They may include novel polymeric materials, encapsulation techniques, or surface modifications to enhance BA, stability, and therapeutic efficacy 94.
Table 7: List of several marketed preparation available microsphere for various targeting
|
API/Drug |
Manufacturing Company |
Commercial Marketed Name |
Use/Application |
Dose |
|
Risperidone |
Janssen Pharmaceuticals, Inc. |
RISPERDAL CONSTA® |
Schizophrenia |
12.5, 25, 37.5, & 50 mg (3) |
|
Naltrexone |
Alkermes |
Vivitrol® |
Alcohol dependence |
380 mg delivered intramuscularly (IM) |
|
Paclitaxel |
Abraxis BioScience |
Abraxane ® |
Cancer Treatment |
260 mg/m² every 3 weeks |
|
Octreotide acetate |
Novartis Pharmaceuticals Corporation |
Sandostatin® LAR |
Alcoholism |
50 mcg three times daily |
|
Triptorelin |
Pfizer |
Trelstar™ depot Decapeptyl® SR |
Prostate cancer |
3.75 mg |
|
Buserelin |
Sanofi-Aventis |
Suprecur® MP |
--- |
--- |
|
Minocycline |
Orapharma |
Arestin® |
--- |
--- |
|
Glatiramer Acetate |
Teva Pharmaceutical Industries |
Copaxone ® |
Multiple Sclerosis |
20 mg/day |
This Table 7 explained the various marketed preparations mentioned in the above discussion with brief details. These preparations demonstrate the clinical utility and commercial success of microsphere and microcapsule technologies.
Recent developments have demonstrated their potential in enhancing therapeutic efficacy, improving drug stability, and enabling controlled release mechanisms. The growing number of patents highlights the increasing interest and investment in this field, reflecting significant progress in formulation techniques, scalability, and diverse applications 96. These advancements, challenges such as scalability, regulatory complexities, and clinical translation remain key barriers. Continued research, innovation, and interdisciplinary collaboration will be crucial in addressing these hurdles, paving the way for the commercialization and widespread adoption of these promising technologies in pharmaceuticals, nutraceuticals, and other industries 95-97. Microencapsulated nanocarriers stand poised to revolutionize healthcare, offering more effective, targeted, and patient-friendly therapeutic solutions.
The clinical trial status of microencapsulation refers to the current phase and progress of clinical studies evaluating the safety, efficacy, and therapeutic benefits of drugs or bioactive compounds delivered through microencapsulation technology. Microencapsulation involves enclosing active ingredients within a protective coating to enhance stability, control release, and improve BA. Clinical trials in this area assess their applications in fields such as targeted drug delivery, sustained-release formulations, and protection of sensitive compounds, ensuring they meet regulatory requirements for human use 97-98.
The various clinical trials conducted for microencapsulation nanocarriers such as microsphere and microcapsules with their details mentioned in the Table 8 as below following.
Table 8: List of clinical trials data on microspheres/microcapsules/microencapsulation
|
Study Title |
Study Type |
NCT Number |
Status |
Conditions |
Interventions |
Sponsor |
|
Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study (RESiN) |
Observational |
NCT02685631 |
Completed |
Localized Non-Resectable Adult Liver Carcinoma |
Yttrium-90 Resin Microspheres |
Vanderbilt-Ingram Cancer Center |
|
Comparison of Pain After Uterine Artery Embolization Using Gelatin Microsphere or Tris-acryl Gelatin Microsphere |
Interventional
|
NCT05086770 |
--- |
Uterine Myoma, Uterine Fibroid |
Device: Gelatin microsphere (Nexsphere™)Device: Embosphere |
Next Biomedical Co., Ltd. |
|
Progesterone Microspheres Pharmacokinetic - Pharmacodynamic (PK-PD) Study |
NCT01176175 |
Phase-I |
Infertility |
Progesterone |
Productos Científicos S. A. de C. V. |
|
|
A Study Comparing Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO ® Gel Microsphere, 0.1% in the Treatment of Acne Vulgaris |
NCT04883736 |
Early Phase I |
Acne Vulgaris |
Tretinoin Gel Microsphere, 0.1% |
Taro Pharmaceuticals USA |
|
|
Bioequivalence Study for Crizotinib Encapsulated Microsphere Formulation (eMS) |
NCT04856293 |
Phase 1 |
Healthy Participants |
Crizotinib |
Pfizer |
|
|
Docetaxel Lipid Microsphere (DT-LM) for Injection in Chemotherapy Patients |
NCT01611961 |
Advanced Cancer |
DT-LM, Docetaxel |
Shenyang Pharmaceutical University |
||
|
Evaluate Taste and Relative Bioavailability of Two Microsphere Formulations of Crizotinib in Healthy Participants |
Interventional |
NCT03978143 |
Completed (Phase I) |
Healthy Volunteers |
Treatment A,B,C etc. |
Pfizer |
This Table 8 explained all clinical trials conducted and concluded the research in the field of microencapsulation. These trials often cover preclinical studies, Phase I (safety), Phase II (efficacy), and later phases for broader evaluations.
The future prospectus of Novel Nanocarriers Microencapsulation and its potential to revolutionize DDs. The integration of nanocarriers with microencapsulation opens avenues for creating more efficient, targeted, and controlled-release formulations 99. The future advancements may focus on:
These innovations could lead to breakthroughs in healthcare, providing safer, more effective treatments for various diseases 102. The various challenges include several technical, regulatory, and clinical trials discussed as below following:
These challenges require interdisciplinary collaboration, advanced research, and supportive regulatory frameworks.
The field of nanocarrier microencapsulation presents significant opportunities for the evolution of drug delivery systems, providing cutting-edge solutions for targeted therapies, improved drug stability, and broader therapeutic uses. The incorporation of new technologies such as AI and 3D printing enhances its capability to transform precision medicine. Nevertheless, to fully harness this potential, it is crucial to tackle considerable challenges, including stability concerns, regulatory obstacles, patent intricacies, and the substantial costs associated with clinical implementation. Collaborative initiatives among research institutions, industry players, and regulatory bodies are vital to overcoming these challenges 106. By capitalizing on technological advancements and addressing existing issues, nanocarrier microencapsulation has the potential to revolutionize healthcare, making treatments safer, more effective, and more accessible to meet a variety of medical needs 107-109.
CONCLUSION
The comprehensive review of novel nanocarriers and microencapsulation technologies highlights their transformative potential in drug delivery, offering solutions for enhanced bioavailability (BA), controlled release, and targeted delivery. Recent developments in drug delivery systems (DDs), such as liposomes, niosomes, solid lipid NPs, and polymeric formulations, highlight their versatility across a range of therapeutic fields. An increase in patent applications indicates a robust drive for innovation aimed at addressing current challenges in pharmacological treatments. Additionally, clinical trials are demonstrating the potential of these technologies in real-world applications, showing encouraging results in areas like oncology, infectious diseases, and chronic conditions. Future investigations need to tackle issues related to scalability, regulatory compliance, and long-term safety to facilitate the broader acceptance of these systems in clinical settings. By aligning technological advancements with patient-focused outcomes, nanocarriers and microencapsulation are poised to transform the future of modern therapeutics.
LIST OF ABBREVIATIONS
PPs: Pantoprazole Sodium; BA: Bioavailability; HPMC: Hydroxy Propyl methyl cellulose; DCM: Dichloromethane; DDs: Drug Delivery Systems; AI: Artificial Intelligence; NPs: Nanoparticle; US: United Sate; EP: European Patent; CA: Canada; CN: China; WIPO: World Intellectual Property Organization.
Acknowledgement: The publication and support of writing the review article, I corresponding author with my co-author would like to thanks my guide Mr. Rahul Pal (Assistant Professor, Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India) for his valuable support and guidance towards the whole journey of my first publication.
Ethical Approval: Not applicable.
Consent for Publication: Not applicable.
Human and Animal Ethical Right: Not applicable.
Conflict of Interest: The authors declare no conflict of interest, and no funding was required to conduct these review data.
Availability of Data And Materials: The data supporting this study’s findings will be available in the cited references.
Funding: The research received no external funding.
Author Contribution: All authors have equal contribution in the preparation of manuscript and compilation.
REFERENCES
1. Adepu S, Ramakrishna S. Controlled drug delivery systems: current status and future directions. Molecules. 2021 Sep 29;26(19):5905. https://doi.org/10.3390/molecules26195905 PMid:34641447 PMCid:PMC8512302
2. Park K. Controlled drug delivery systems: past forward and future back. Journal of Controlled Release. 2014 Sep 28;190:3-8. https://doi.org/10.1016/j.jconrel.2014.03.054 PMid:24794901 PMCid:PMC4142099
3. Senapati S, Mahanta AK, Kumar S, Maiti P. Controlled drug delivery vehicles for cancer treatment and their performance. Signal transduction and targeted therapy. 2018 Mar 16;3(1):7. https://doi.org/10.1038/s41392-017-0004-3 PMid:29560283 PMCid:PMC5854578
4. Pal R, Pandey P, Khadam VK, Chawra HS, Singh RP. The diverse marketed formulations of advanced nano drug carrier vehicles (and CVS) in different biomedical treatments: a complete descriptive review. International Journal of Pharma Professional's Research (IJPPR). 2024 Jun 4;15(2):1-6. https://doi.org/10.69580/IJPPR.15.2.2024.1-18
5. Mandal RK, Saini P, Pal R, Pandey P, Dubey A. Coating Tablets, Compositions, Recent Advancement and Current Status: A Comprehensive Review. Journal of Drug Delivery & Therapeutics. 2024 Oct 1;14(10):182-95. https://doi.org/10.22270/jddt.v14i10.6809
6. Sharif N, Khoshnoudi-Nia S, Jafari SM. Nano/microencapsulation of anthocyanins; a systematic review and meta-analysis. Food Research International. 2020 Jun 1;132:109077. https://doi.org/10.1016/j.foodres.2020.109077 PMid:32331692
7. Pinto TV, Silva CA, Siquenique S, Learmonth DA. Micro-and nanocarriers for encapsulation of biological plant protection agents: A systematic literature review. ACS Agricultural Science & Technology. 2022 Aug 15;2(5):838-57. https://doi.org/10.1021/acsagscitech.2c00113
8. Jafari SM. An overview of nanoencapsulation techniques and their classification. Nanoencapsulation technologies for the food and nutraceutical industries. 2017 Jan 1:1-34. https://doi.org/10.1016/B978-0-12-809436-5.00001-X
9. Gul S, Miano TF, Mujeeb A, Chachar M, Majeedano MI, Murtaza G, Ahmed W, Khanzada YA, Ansari M. Advancements in Nutraceutical Delivery: Integrating Nanotechnology and Microencapsulation for Enhanced Efficacy and Bioavailability. Matrix Science Pharma. 2024 Jan 1;8(1):1-6. https://doi.org/10.4103/mtsp.mtsp_1_24
10. Peanparkdee M, Iwamoto S, Yamauchi R. Microencapsulation: a review of applications in the food and pharmaceutical industries. Reviews in Agricultural Science. 2016;4:56-65. https://doi.org/10.7831/ras.4.56
11. Paulo F, Santos L. Design of experiments for microencapsulation applications: A review. Materials Science and Engineering: C. 2017 Aug 1;77:1327-40. https://doi.org/10.1016/j.msec.2017.03.219 PMid:28532010
12. Choudhury N, Meghwal M, Das K. Microencapsulation: An overview on concepts, methods, properties and applications in foods. Food Frontiers. 2021 Dec;2(4):426-442. https://doi.org/10.1002/fft2.94
13. Pal R, Pandey P, Nogai L, Anand A, Suthar P, SahdevKeskar M, Kumar V. The future perspectives and novel approach on gastro retentive drug delivery system (GRDDS) with currrent state. Journal of Population Therapeutics and Clinical Pharmacology. 2023 Sep 19;30(17):594-613. https://doi.org/10.53555/jptcp.v30i17.2852
14. Saini L, Dubey A, Pal R, Pandey P, Mandal RK. Synthetic and Natural Polymers Enhancing Drug Delivery and Their Treatment: A Comprehensive Review. Journal of Drug Delivery & Therapeutics. 2024 Oct 1;14(10). https://doi.org/10.22270/jddt.v14i10.6802
15. Prasad DN. Microencapsulation And Its Various Aspects: A Review. International Journal. 2016;4(6):2094-108. https://doi.org/10.21474/IJAR01/726
16. Snehal MD, Swapna KR, Manoj NM, Chandrakant MS. Microencapsulation: A review. Research Journal of Pharmacy and Technology. 2013 Sep 1;6(9):954.
17. Pal R, Pandey P, Anand A, Saxena A, Thakur SK, Malakar RK, Kumar V. The Pharmaceutical Polymer's; A current status in drug delivery: A Comprehensive Review. Journal of Survey in Fisheries Sciences. 2023 Mar 16:3682-92.
18. Augustin MA, Sanguansri L. Microencapsulation technologies. Engineering Foods for Bioactives Stability and Delivery. 2017:119-142. https://doi.org/10.1007/978-1-4939-6595-3_4
19. Huang K, Yuan Y, Baojun X. A critical review on the microencapsulation of bioactive compounds and their application. Food Reviews International. 2023 Jul 4;39(5):2594-634. https://doi.org/10.1080/87559129.2021.1963978
20. Lu Y, Park K. Microencapsulation: methods and pharmaceutical applications. Encyclopedia of pharmaceutical science and technology, 4th edn. Informa Healthcare, USA. 2012.
21. Sahil K, Akanksha M, Premjeet S, Bilandi A, Kapoor B. Microsphere: A review. Int. J. Res. Pharm. Chem. 2011;1(4):1184-98.
22. Rahul Pal, Prachi Pandey, Himmat Singh Chawra, Ravindra Pal Singh, Niosomal as Potential Vesicular Drug Nano-carriers for the Treatment of Tuberculosis (TB), Nanoscience & Nanotechnology-Asia; 2025;15(1):e22106812323829. https://doi.org/10.2174/0122106812323829240919050438
23. Qiao J, Hu X, Guan P, Zhao Y, Tian W. Preparation and development of pharmaceutical microcapsules. Progress in Chemistry. 2008 Jan 24;20(01):171.
24. Lengyel M, Kállai-Szabó N, Antal V, Laki AJ, Antal I. Microparticles, microspheres, and microcapsules for advanced drug delivery. Scientia Pharmaceutica. 2019;87(3):20. https://doi.org/10.3390/scipharm87030020
25. Jyothi SS, Seethadevi A, Prabha KS, Muthuprasanna P, Pavitra P. Microencapsulation: a review. Int. J. Pharm. Biol. Sci. 2012;3(2):509-31.
26. Khandbahale SV. Microencapsulation-A novel approach in drug delivery: A review. Asian Journal of Research in Pharmaceutical Science. 2020;10(1):39-50. https://doi.org/10.5958/2231-5659.2020.00009.0
27. Lobel BT, Baiocco D, Al-Sharabi M, Routh AF, Zhang Z, Cayre OJ. Current challenges in microcapsule designs and microencapsulation processes: A review. ACS applied materials & interfaces. 2024 Jul 23;16(31):40326-40355. https://doi.org/10.1021/acsami.4c02462 PMid:39042830 PMCid:PMC11311140
28. Wong CY, Al-Salami H, Dass CR. Microparticles, microcapsules and microspheres: A review of recent developments and prospects for oral delivery of insulin. International journal of pharmaceutics. 2018 Feb 15;537(1-2):223-244. https://doi.org/10.1016/j.ijpharm.2017.12.036 PMid:29288095
29. Krishna Sailaja A, Jyothika M. A review on microcapsules. CIBTech Journal of Pharmaceutical Sciences. 2014;4(2):26-33.
30. Bansode SS, Banarjee SK, Gaikwad DD, Jadhav SL, Thorat RM. Microencapsulation: a review. International journal of pharmaceutical sciences review and research. 2010 Mar;1(2):38-43.
31. Pal R, Pandey P, Rai B, Koli M, Chakrabarti M, Thakur P, Rizwan M, Saxena A. Chitosan: as highly potential biopolymer obtainable in several advance drug delivery systems including biomedical applications. Environmental science. 2023;3(4).
32. Bah MG, Bilal HM, Wang J. Fabrication and application of complex microcapsules: A review. Soft Matter. 2020;16(3):570-590. https://doi.org/10.1039/C9SM01634A PMid:31845956
33. Pal R, Pandey P, Thakur S, Chanana A, Singh RP. Biodegradable Polymer's Enhancing Drug Delivery Activity In Different Novel Drug Delivery System. WJPPS. 2022 Nov 22;12(1):2046-69.
34. Eghbal N, Liao W, Dumas E, Azabou S, Dantigny P, Gharsallaoui A. Microencapsulation of natural food antimicrobials: Methods and applications. Applied Sciences. 2022 Apr 11;12(8):3837. https://doi.org/10.3390/app12083837
35. Singh MN, Hemant KS, Ram M, Shivakumar HG. Microencapsulation: A promising technique for controlled drug delivery. Research in pharmaceutical sciences. 2010 Jul;5(2):65.
36. Bakry AM, Abbas S, Ali B, Majeed H, Abouelwafa MY, Mousa A, Liang L. Microencapsulation of oils: A comprehensive review of benefits, techniques, and applications. Comprehensive reviews in food science and food safety. 2016 Jan;15(1):143-182. https://doi.org/10.1111/1541-4337.12179 PMid:33371581
37. Estevinho BN, Rocha F, Santos L, Alves A. Microencapsulation with chitosan by spray drying for industry applications-A review. Trends in food science & technology. 2013 Jun 1;31(2):138-155. https://doi.org/10.1016/j.tifs.2013.04.001
38. Pal R, Pandey P, Nogai L. The Advanced Approach in The Development of Targeted Drug Delivery (TDD) With Their Bio-Medical Applications: A Descriptive Review. International Neurourology Journal. 2023 Oct 7;27(4):40-58.
39. Shamaei S, Seiiedlou SS, Aghbashlo M, Tsotsas E, Kharaghani A. Microencapsulation of walnut oil by spray drying: Effects of wall material and drying conditions on physicochemical properties of microcapsules. Innovative food science & emerging technologies. 2017 Feb 1;39:101-112. https://doi.org/10.1016/j.ifset.2016.11.011
40. Manjanna KM, Shivakumar B, Kumar TP. Microencapsulation: an acclaimed novel drug-delivery system for NSAIDs in arthritis. Critical Reviews™ in Therapeutic Drug Carrier Systems. 2010;27(6). https://doi.org/10.1615/CritRevTherDrugCarrierSyst.v27.i6.20 PMid:21175420
41. Poshadri A, Aparna K. Microencapsulation technology: a review. Journal of Research ANGRAU. 2010;38(1):86-102.
42. Arabpour Z, Fath-Bayati L, Sefat F, Navaei-Nigjeh M. Microencapsulation: Extrusion. InPrinciples of Biomaterials Encapsulation: Volume One 2023 Jan 1 (pp. 393-409). Woodhead Publishing. https://doi.org/10.1016/B978-0-323-85947-9.00015-7
43. Huang HJ, Yuan WK, Chen XD. Microencapsulation based on emulsification for producing pharmaceutical products: A literature review. Developments in Chemical Engineering and Mineral Processing. 2006;14(3‐4):515-544. https://doi.org/10.1002/apj.5500140318
44. Frey C. Fluid bed coating-based microencapsulation. InMicroencapsulation in the food industry 2023 Jan 1 (pp. 83-115). Academic Press. https://doi.org/10.1016/B978-0-12-821683-5.00024-8
45. Muhoza B, Yuyang H, Uriho A, Harindintwali JD, Liu Q, Li Y. Spray-and freeze-drying of microcapsules prepared by complex coacervation method: A review. Food Hydrocolloids. 2023 Jul 1;140:108650. https://doi.org/10.1016/j.foodhyd.2023.108650
46. Meena KK, Taneja NK, Ojha A, Meena S. Application of spray-drying and freeze-drying for microencapsulation of lactic acid bacteria: a review. Ann Phytomed. 2023;12(1):706-716. https://doi.org/10.54085/ap.2023.12.1.76
47. Yan C, Kim SR. Microencapsulation for pharmaceutical applications: a review. ACS Applied Bio Materials. 2024 Feb 6;7(2):692-710. https://doi.org/10.1021/acsabm.3c00776 PMid:38320297
48. Wang R, Bao Q, Clark AG, Wang Y, Zhang S, Burgess DJ. Characterization and in vitro release of minocycline hydrochloride microspheres prepared via coacervation. International Journal of Pharmaceutics. 2022 Nov 25;628:122292. https://doi.org/10.1016/j.ijpharm.2022.122292 PMid:36252639
49. Tiwari S, Verma P. Microencapsulation technique by solvent evaporation method (Study of effect of process variables). International journal of pharmacy & life sciences. 2011 Aug 1;2(8).
50. Jelvehgari M, Montazam SH. Comparison of microencapsulation by emulsion-solvent extraction/evaporation technique using derivatives cellulose and acrylate-methacrylate copolymer as carriers. Jundishapur journal of natural pharmaceutical products. 2012;7(4):144. https://doi.org/10.5812/jjnpp.3986 PMid:24624173 PMCid:PMC3941872
51. Bakan JA. Microencapsulation using coacervation/phase separation techniques. InControlled release technologies 2019 Oct 16 (pp. 83-105). CRC Press. https://doi.org/10.1201/9780429287428-4
52. Jyothi NV, Prasanna PM, Sakarkar SN, Prabha KS, Ramaiah PS, Srawan GY. Microencapsulation techniques, factors influencing encapsulation efficiency. Journal of microencapsulation. 2010 May 1;27(3):187-197. https://doi.org/10.3109/02652040903131301 PMid:20406093
53. Dubey R, Shami TC, Rao KU. Microencapsulation technology and applications. Defence Science Journal. 2009;59(1):82-95.
54. Andrianov AK, Chen J, Payne LG. Preparation of hydrogel microspheres by coacervation of aqueous polyphosphazene solutions. Biomaterials. 1998 Jan 1;19(1-3):109-115. https://doi.org/10.1016/S0142-9612(97)00227-5 PMid:9678857
55. Makino K, Fujita Y, Takao KI, Kobayashi S, Ohshima H. Preparation and properties of thermosensitive hydrogel microcapsules. Colloids and Surfaces B: Biointerfaces. 2001 Aug 1;21(4):259-263. https://doi.org/10.1016/S0927-7765(00)00191-0 PMid:11397628
56. Khan MG, Gauttam V, Chandel HS, Ali A, Tariq K. Development of microencapsulation: A review of literature. Int J Sci Stud. 2016;5(4):264-8.
57. Kumar KS, Tejbe SK, Banu S, Lakshmi PN, Bhowmik D. Microencapsulation technology. Indian Journal of Research in Pharmacy and Biotechnology. 2013 May 1;1(3):324.
58. Cid-Samamed A, Rakmai J, Mejuto JC, Simal-Gandara J, Astray G. Cyclodextrins inclusion complex: Preparation methods, analytical techniques and food industry applications. Food Chemistry. 2022 Aug 1;384:132467. https://doi.org/10.1016/j.foodchem.2022.132467 PMid:35219231
59. Ricardo F, Pradilla D, Luiz R, Alvarez Solano OA. A multi-scale approach to microencapsulation by interfacial polymerization. Polymers. 2021 Feb 22;13(4):644. https://doi.org/10.3390/polym13040644 PMid:33671501 PMCid:PMC7926481
60. Cho JS, Kwon A, Cho CG. Microencapsulation of octadecane as a phase-change material by interfacial polymerization in an emulsion system. Colloid and polymer science. 2002 Mar;280:260-266. https://doi.org/10.1007/s00396-001-0603-x
61. Saadi S, Nacer NE, Chenaker H, Ariffin AA, Ghazali HM, Saari N, Mohammed AS, Anwar F, Hamid AA. A review on trends in microencapsulation of bioactive compounds: coating materials, design, and applications. European Food Research and Technology. 2023 Dec;249(12):3123-3319. https://doi.org/10.1007/s00217-023-04354-2
62. Abdel-Mageed HM, AbuelEzz NZ, Radwan RA, Mohamed SA. Nanoparticles in nanomedicine: a comprehensive updated review on current status, challenges and emerging opportunities. Journal of microencapsulation. 2021 Aug 18;38(6):414-436. https://doi.org/10.1080/02652048.2021.1942275 PMid:34157915
63. Homar M, Dreu R, Kerč J, Gašperlin M. Preparation and evaluation of celecoxib-loaded microcapsules with self-microemulsifying core. Journal of microencapsulation. 2009 Sep 1;26(6):479-484. https://doi.org/10.1080/02652040802383839 PMid:19694601
64. Assadpour E, Mahdi Jafari S. A systematic review on nanoencapsulation of food bioactive ingredients and nutraceuticals by various nanocarriers. Critical reviews in food science and nutrition. 2019 Oct 28;59(19):3129-3151. https://doi.org/10.1080/10408398.2018.1484687 PMid:29883187
65. Simi SP, Saraswathi R, Sankar C, Krishnan PN, Dilip C, Ameena K. Formulation and evaluation of Albendazole microcapsules for colon delivery using chitosan. Asian Pacific Journal of Tropical Medicine. 2010 May 1;3(5):374-378. https://doi.org/10.1016/S1995-7645(10)60091-0
66. Yadav AV, Shete AS, Dabke AP, Shinde VR. Formulation and in vitro evaluation of Aceclofenac microcapsules. Int. J. Pharm. Techn. Res. 2009 Apr;1:135-8.
67. Pandya HV. Formulation and evaluation of microcapsules of trihexyphenidyle hydrochloride by solvent evaporation method. International Journal of Pharmaceutical Sciences and Research. 2012 Feb 1;3(2):539.
68. Shekhar K, Madhu MN, Madhavi BB, Arjun G, Pradeep B, Banji D. Formulation and Evaluation of Cefotaxime Sodium Microcapsules. Journal of Pharmacy Research. 2011 Feb;4(2):317-22.
69. Bal T, Sengupta S, Murthy PN. Formulation and evaluation of carvedilol microcapsules using Eudragit NE30D and sodium alginate. Brazilian Journal of Pharmaceutical Sciences. 2013;49:889-901. https://doi.org/10.1590/S1984-82502013000400029
70. AppaRao B, Shivalingam MR, Reddy YK, Sunitha N, Jyothibasu T, Shyam T. Design and evaluation of sustained release microcapsules containing diclofenac sodium. Int J Pharm Biomed Res. 2010;1(3):90-93.
71. Mukherjee B, Mahanti B, Panda P, Mahapatra S. Preparation and evaluation of verapamil hydrochloride microcapsules. American journal of therapeutics. 2005 Sep 1;12(5):417-244. https://doi.org/10.1097/01.mjt.0000162014.43743.e0 PMid:16148427
72. Pradeep B, Nagamadhu M, Banji D, Madhavi BB, Arjun G, Shekhar K. Formulation and evaluation of valacyclovir hydrochloride microcapsules. Int J Pharm Pharm Sci. 2011;3(2):92-96.
73. Raj BS, Pancholi J, Samraj PI. Design and evaluation of floating microspheres of pantoprazole sodium. Pharmaceutical and Biosciences Journal. 2015 Sep 23:09-17. https://doi.org/10.20510/ukjpb/3/i6/87831
74. Raj BS, Nair RS, Samraj PI. Formulation and evaluation of coated microspheres for colon targeting. Journal of Applied Pharmaceutical Science. 2013 Sep 18;3(8,):S68-S74. https://doi.org/10.7324/JAPS.2013.38.S11
75. Gaur PK, Mishra S, Bajpai M. Formulation and evaluation of controlled-release of telmisartan microspheres: In vitro/in vivo study. Journal of food and drug analysis. 2014 Dec 1;22(4):542-548. https://doi.org/10.1016/j.jfda.2014.05.001 PMid:28911472 PMCid:PMC9354994
76. Ramachandran S, Nandhakumar S, Dhanaraju MD. Formulation and characterization of glutaraldehyde cross-linked chitosan biodegradable microspheres loaded with famotidine. Tropical Journal of Pharmaceutical Research. 2011;10(3). https://doi.org/10.4314/tjpr.v10i3.13
77. Hardenia SS, Jain A, Patel R, Kaushal A. Formulation and evaluation of mucoadhesive microspheres of ciprofloxacin. Journal of Advanced Pharmacy Education and research. 2011;1(4-2011):214-224.
78. Roy T, Chatterjee TK. Formulation and evaluation of microspheres of anti-inflammatory drug diacerein pre-pared by ionotropic gelation method. Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.). 2022 Jul 7;8(1). https://doi.org/10.59049/2790-0231.1145
79. Patel JK, Patel RP, Amin AF, Patel MM. Formulation and evaluation of mucoadhesive glipizide microspheres. AAps PharmSciTech. 2005 Mar;6:E49-E55. https://doi.org/10.1208/pt060110 PMid:16353963 PMCid:PMC2750411
80. Yahoum MM, Toumi S, Tahraoui H, Lefnaoui S, Kebir M, Amrane A, Assadi AA, Zhang J, Mouni L. Formulation and evaluation of xanthan gum microspheres for the sustained release of metformin hydrochloride. Micromachines. 2023 Mar 6;14(3):609. https://doi.org/10.3390/mi14030609 PMid:36985017 PMCid:PMC10055444
81. Dubey M, Kesharwani P, Tiwari A, Chandel R, Raja K, Sivakumar T. Formulation and evaluation of floating microsphere containing anti diabetic drug. Int J Pharm Chem Sci. 2012;1(3):1038-47.
82. Reddy BV, Krishnaveni K. Formulation and evaluation of efavirenz microspheres. Der Pharmacia letters. 2015;7(6):1-9.
83. Enriquez GG, Rizvi SA, D'Souza MJ, Do DP. Formulation and evaluation of drug-loaded targeted magnetic microspheres for cancer therapy. International Journal of Nanomedicine. 2013 Apr 10:1393-1402. https://doi.org/10.2147/IJN.S43479 PMid:23630421 PMCid:PMC3626373
84. Agrawal GR, Wakte P, Shelke S. Formulation, physicochemical characterization and in vitro evaluation of human insulin-loaded microspheres as potential oral carrier. Progress in biomaterials. 2017 Sep;6:125-136. https://doi.org/10.1007/s40204-017-0072-z PMid:28864917 PMCid:PMC5597563
85. Dey S, Pramanik S, Malgope A. Formulation and optimization of sustained release stavudine microspheres using response surface methodology. International Scholarly Research Notices. 2011;2011(1):627623. https://doi.org/10.5402/2011/627623 PMid:22389855 PMCid:PMC3263718
86. Dhawale SC, Bankar AS, Patro MN. Formulation and evaluation porous microspheres of 5-fluorouracil for colon targeting. Int. J. Pharm. Tech. Res. 2010 Apr;2(2):1112-8.
87. Patil P, Singh S, Sarvanan J. Preparation and evaluation of microspheres of flurbiprofen. Int J Pharm Sci Res. 2018 Dec 1;9(12):5388-93.
88. Parashar V, Ahmad D, Gupta SP, Upmanyu N, Parashar N, Mudgal V. Formulation and evaluation of biodegradable microspheres of tinidazole. International Journal of Drug Delivery. 2010 Jul 1;2(3). https://doi.org/10.5138/ijdd.2010.0975.0215.02034
89. Prajapati CV, Patel RP, Prajapati BG. Formulation, optimization and evaluation of sustained release microsphere of ketoprofen. Journal of Pharmacy and Bioallied Sciences. 2012 Mar 1;4(Suppl 1):S101-103. https://doi.org/10.4103/0975-7406.94156 PMid:23066178 PMCid:PMC3467827
90. Babu AK, Teja NB, Ramakrishna B, Kumar BB, Reddy GV. Formulation and evaluation of double walled microspheres loaded with pantoprazole. Methods. 2011;15:28.
91. Nappinnai M, Kishore V. Formulation and evaluation of microspheres of diltiazem hydrochloride. Indian journal of pharmaceutical Sciences. 2007 Jul 1;69(4):511-514. https://doi.org/10.4103/0250-474X.36935
92. Chakra BK, Karan S, Das B, Debnath S, Chatterjee TK. A controlled release microsphere formulation of an antidiabetic drug and characterization of the microsphere. International Journal of Pharmacy and Pharmaceutical Sciences. 2018;10(10):30-38. https://doi.org/10.22159/ijpps.2018v10i10.27541
93. Ali J, Ali M, Baboota S. Patents on nanoparticulate drug delivery systems-a review. Recent Patents on Drug Delivery & Formulation. 2008 Jan 1;2(1):83-89. https://doi.org/10.2174/187221108783331401 PMid:19075900
94. Righini GC, Prudenzano F. Applications of Glass Micro-and Nanospheres. InGlass Micro-and Nanospheres: Physics and Applications 2019 Aug 15 (pp. 273-334). CRC Press. https://doi.org/10.1201/b22474-8
95. Midha K, Nagpal M, Arora S. Microspheres: a recent update. Int. J. Recent. Sci. Res. 2015 Jul;50(8):5859-67.
96. Virmani T, Gupta J. Pharmaceutical application of microspheres: an approach for the treatment of various diseases. Int J Pharm Sci Res. 2017;8(8):3253-3260.
97. Hossain KM, Patel U, Ahmed I. Development of microspheres for biomedical applications: a review. Progress in biomaterials. 2015 Mar;4:1-9. https://doi.org/10.1007/s40204-014-0033-8 PMid:29470791 PMCid:PMC5151111
98. Calafiore R, Basta G. Clinical application of microencapsulated islets: actual prospectives on progress and challenges. Advanced drug delivery reviews. 2014 Apr 10;67:84-92. https://doi.org/10.1016/j.addr.2013.09.020 PMid:24184490
99. Wong CY, Al-Salami H, Dass CR. Microparticles, microcapsules and microspheres: A review of recent developments and prospects for oral delivery of insulin. International journal of pharmaceutics. 2018 Feb 15;537(1-2):223-244. https://doi.org/10.1016/j.ijpharm.2017.12.036 PMid:29288095
100. Hu M, Guo J, Yu Y, Cao L, Xu Y. Research advances of microencapsulation and its prospects in the petroleum industry. Materials. 2017 Mar 31;10(4):369. https://doi.org/10.3390/ma10040369 PMid:28772728 PMCid:PMC5506935
101. Yan C, Kim SR. Microencapsulation for pharmaceutical applications: a review. ACS Applied Bio Materials. 2024 Feb 6;7(2):692-710. https://doi.org/10.1021/acsabm.3c00776 PMid:38320297
102. Riseh RS, Hassanisaadi M, Vatankhah M, Soroush F, Varma RS. Nano/microencapsulation of plant biocontrol agents by chitosan, alginate, and other important biopolymers as a novel strategy for alleviating plant biotic stresses. International Journal of Biological Macromolecules. 2022 Dec 1;222:1589-604. https://doi.org/10.1016/j.ijbiomac.2022.09.278 PMid:36202330
103. Lopez-Mendez TB, Santos-Vizcaino E, Pedraz JL, Orive G, Hernandez RM. Cell microencapsulation technologies for sustained drug delivery: Latest advances in efficacy and biosafety. Journal of Controlled Release. 2021 Jul 10;335:619-636. https://doi.org/10.1016/j.jconrel.2021.06.006 PMid:34116135
104. Sukhorukov GB, Rogach AL, Garstka M, Springer S, Parak WJ, Muñoz‐Javier A, Kreft O, Skirtach AG, Susha AS, Ramaye Y, Palankar R. Multifunctionalized polymer microcapsules: novel tools for biological and pharmacological applications. Small. 2007 Jun 4;3(6):944-955. https://doi.org/10.1002/smll.200600622 PMid:17487898
105. Sun Q, Yin S, He Y, Cao Y, Jiang C. Biomaterials and encapsulation techniques for probiotics: Current status and future prospects in biomedical applications. Nanomaterials. 2023 Jul 27;13(15):2185. https://doi.org/10.3390/nano13152185 PMid:37570503 PMCid:PMC10421492
106. Neekhra S, Pandith JA, Mir NA, Manzoor A, Ahmad S, Ahmad R, Sheikh RA. Innovative approaches for microencapsulating bioactive compounds and probiotics: An updated review. Journal of Food Processing and Preservation. 2022 Nov;46(11):e16935. https://doi.org/10.1111/jfpp.16935
107. Abdel-Mageed HM, AbuelEzz NZ, Radwan RA, Mohamed SA. Nanoparticles in nanomedicine: a comprehensive updated review on current status, challenges and emerging opportunities. Journal of microencapsulation. 2021 Aug 18;38(6):414-436. https://doi.org/10.1080/02652048.2021.1942275 PMid:34157915
108. Sawant RB, Nikam SP, Roy A, Kumar A, Mohammed OA, Sharma K, Rai AK, Roy A, Gaur A, Verma R. Nanocarriers for nutraceutical delivery: A miniaturized revolution in health. Nano-Structures & Nano-Objects. 2024 Sep 1;39:101321. https://doi.org/10.1016/j.nanoso.2024.101321
109. Ma G, Su ZG, editors. Microspheres and microcapsules in biotechnology: design, preparation and applications. CRC Press; 2013 Jan 29.